Received Mar 6, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | LN4928 | — |
Kinrix-Under age use; Kinrix as 3rd dose Dtap; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a male patient who received DTPa-IPV (Kinrix) (batch number LN4928) for prophylaxis. Previously administered products included Dtap vaccine (received 2 doses on an unknown date). On an unknown date, the patient received Kinrix. On an unknown date, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Kinrix-Under age use) and inappropriate schedule of vaccine administered (Verbatim: Kinrix as 3rd dose Dtap). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 24-FEB-2026 The reporter asked that there were any safety concerns. The reporter did not share the expiration date of the dose or more details. This case is linked with US2026026021 and US2026026562, reported by same reporter for different patients.; Sender's Comments: US-GSK-US2026026021:Same reporter/Different patient US-GSK-US2026026562:Same reporter/Different patient